🚀 VC round data is live in beta, check it out!
Elicera Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Elicera Therapeutics and similar public comparables like Tempest Therapeutics, Marker Therapeutics, Jasper Therapeutics, Skye Bioscience and more.
Elicera Therapeutics Overview
About Elicera Therapeutics
Elicera Therapeutics AB is a Sweden-based clinical-stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments. The company's product portfolio consists of four drug candidates, two in the field of oncolytic viruses (ELC-100 and ELC-201) and two in the field of CAR T-cell treatments (ELC-301 and ELC-401), in addition to a universal CAR T-cell technology platform, iTANK (ELC-001), compatible with any CAR T-cell therapy for a multi-targeted attack on solid tumors.
Founded
2014
HQ
Employees
2
Website
Sectors
Financials (LTM)
EV
$25M
Elicera Therapeutics Financials
Elicera Therapeutics reported last 12-month revenue of — and negative EBITDA of ($994K).
In the same LTM period, Elicera Therapeutics generated — in gross profit, ($994K) in EBITDA losses, and had net loss of ($1M).
Revenue (LTM)
Elicera Therapeutics P&L
In the most recent fiscal year, Elicera Therapeutics reported revenue of — and EBITDA of ($2M).
Elicera Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($994K) | XXX | ($2M) | XXX | XXX | XXX |
| Net Profit | ($1M) | XXX | ($2M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Elicera Therapeutics Stock Performance
Elicera Therapeutics has current market cap of $28M, and enterprise value of $25M.
Market Cap Evolution
Elicera Therapeutics' stock price is $0.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $25M | $28M | -2.1% | XXX | XXX | XXX | $-0.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialElicera Therapeutics Valuation Multiples
Elicera Therapeutics trades at (25.5x) EV/EBITDA.
EV / Revenue (LTM)
Elicera Therapeutics Financial Valuation Multiples
As of April 18, 2026, Elicera Therapeutics has market cap of $28M and EV of $25M.
Equity research analysts estimate Elicera Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elicera Therapeutics has a P/E ratio of (24.5x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28M | XXX | $28M | XXX | XXX | XXX |
| EV (current) | $25M | XXX | $25M | XXX | XXX | XXX |
| EV/EBITDA | (25.5x) | XXX | (13.4x) | XXX | XXX | XXX |
| EV/EBIT | (25.6x) | XXX | (13.0x) | XXX | XXX | XXX |
| P/E | (24.5x) | XXX | (14.8x) | XXX | XXX | XXX |
| EV/FCF | (11.0x) | XXX | (11.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Elicera Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Elicera Therapeutics Margins & Growth Rates
Elicera Therapeutics' revenue in the last fiscal year grew by —.
Elicera Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Elicera Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | (203%) | XXX | (179%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Elicera Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Elicera Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Tempest Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Marker Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Jasper Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Skye Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Lantern Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elicera Therapeutics M&A Activity
Elicera Therapeutics acquired XXX companies to date.
Last acquisition by Elicera Therapeutics was on XXXXXXXX, XXXXX. Elicera Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Elicera Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialElicera Therapeutics Investment Activity
Elicera Therapeutics invested in XXX companies to date.
Elicera Therapeutics made its latest investment on XXXXXXXX, XXXXX. Elicera Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Elicera Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Elicera Therapeutics
| When was Elicera Therapeutics founded? | Elicera Therapeutics was founded in 2014. |
| Where is Elicera Therapeutics headquartered? | Elicera Therapeutics is headquartered in Sweden. |
| How many employees does Elicera Therapeutics have? | As of today, Elicera Therapeutics has over 2 employees. |
| Is Elicera Therapeutics publicly listed? | Yes, Elicera Therapeutics is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of Elicera Therapeutics? | Elicera Therapeutics trades under ELIC ticker. |
| When did Elicera Therapeutics go public? | Elicera Therapeutics went public in 2021. |
| Who are competitors of Elicera Therapeutics? | Elicera Therapeutics main competitors are Tempest Therapeutics, Marker Therapeutics, Jasper Therapeutics, Skye Bioscience. |
| What is the current market cap of Elicera Therapeutics? | Elicera Therapeutics' current market cap is $28M. |
| Is Elicera Therapeutics profitable? | No, Elicera Therapeutics is not profitable. |
| What is the current EBITDA of Elicera Therapeutics? | Elicera Therapeutics has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Elicera Therapeutics? | Current EBITDA multiple of Elicera Therapeutics is (25.5x). |
| What is the current FCF of Elicera Therapeutics? | Elicera Therapeutics' last 12 months FCF is ($2M). |
| What is the current EV/FCF multiple of Elicera Therapeutics? | Current FCF multiple of Elicera Therapeutics is (11.0x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.